BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28754615)

  • 1. Role of transforming growth factor-β1 in triple negative breast cancer patients.
    Zhang M; Wu J; Mao K; Deng H; Yang Y; Zhou E; Liu J
    Int J Surg; 2017 Sep; 45():72-76. PubMed ID: 28754615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
    Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
    Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
    Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
    J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
    Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
    Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
    Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
    PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
    Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
    J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
    Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
    Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implication of leucine zipper/EF hand-containing transmembrane-1 overexpression in the prognosis of triple-negative breast cancer.
    Wang CA; Liu Q; Chen Y; Liu S; Xu J; Cui X; Zhang Y; Piao L
    Exp Mol Pathol; 2015 Apr; 98(2):254-9. PubMed ID: 25617527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.